Floatz logo

Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells

Progressive Disease

M.D. Anderson Cancer CenterCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Progressive Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Jonsson Comprehensive Cancer Center
Phase 2B
Fludarabine
Jonsson Comprehensive Cancer Center
Phase 2B
Axicabtagene Ciloleucel
Jonsson Comprehensive Cancer Center
Phase 2CCC
Anakinra
Jonsson Comprehensive Cancer Center
Phase 2CCC
Autologous Humanized Anti-Cd22 Chimeric Antigen Receptor T Cells
M.D. Anderson Cancer Center
Phase 1/2CCC

View all 16 →

Same molecule, other indications

Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells is also rated in:

CD22 PositiveDormant
CCC
Indicative ·
48 / 100
View asset →
CD19 PositiveDormant
CCC
Indicative ·
48 / 100
View asset →
Recurrent Non-Hodgkin LymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →